North America’s medical devices industry saw a drop of 7.48% in deal activity during January 2022, when compared with the last 12-month average, led by Owens & Minor’s $1.6bn acquisition of Apria, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 99 medical devices industry deals worth $4.7bn were announced for the region in January 2022, against the 12-month average of 107 deals.

Of all the deal types, venture financing saw most activity in January 2022 with 57 transactions, representing a 57.6% share for the region.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In second place was M&A with 33 deals, followed by private equity deals with nine transactions, respectively capturing a 33.3% and 9.1% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $3.27bn, while venture financing and private equity deals totalled $1.17bn and $250m, respectively.

North America medical devices industry deals in January 2022: Top deals

The top five medical devices deals accounted for 67.4% of the overall value during January 2022.

The combined value of the top five medical devices deals stood at $3.16bn, against the overall value of $4.7bn recorded for the month.

The top five medical devices industry deals of January 2022 tracked by GlobalData were:

1) Owens & Minor $1.6bn acquisition deal with Apria

2) The $623m acquisition of GeneDX by Sema4 OpCo

3) ConvaTec Group $450m acquisition deal with Triad Life Sciences

4) The $250m private equity of Fluidigm by Casdin Capital and Viking Global Investors

5) Maravai LifeSciences Holdings $240m acquisition deal with MyChem